Finance

Lists
Why is CRVS down 6,37%?
Dive Deeper
CRVS:NASDAQ
Corvus Pharmaceuticals Inc
US$9,41
-6,37%
(-0,64) 1D
US$9,41
0,00% (0,00)
After hours
Closed: 13 ຕ.ລ., 16 ໂມງ 0 ນາທີ 01 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRVS...
Open
US$9,99
High
US$10,03
Low
US$9,32
Mkt. cap
791,58 ລ້ານ
Avg. vol.
1,17 ລ້ານ
Volume
1,69 ລ້ານ
52-wk high
US$26,95
52-wk low
US$6,39
EPS
US$-0,62
Beta
1,44
Shares outstanding
84,12 ລ້ານ
No. of employees
37
Open
US$9,99
High
US$10,03
Low
US$9,32
Mkt. cap
791,58 ລ້ານ
Avg. vol.
1,17 ລ້ານ
Volume
1,69 ລ້ານ
52-wk high
US$26,95
52-wk low
US$6,39
EPS
US$-0,62
Beta
1,44
Shares outstanding
84,12 ລ້ານ
No. of employees
37
News stories
From web sources and news partners
Benzinga
Benzinga
·
1 ມື້ກ່ອນ
Corvus Pharma Q2 2026 Earnings Call Transcript
About Corvus Pharmaceuticals Inc
CEO-
Employees37
Founded2014
HeadquartersBurlingame, ແຄລິຟໍເນຍ, ສະຫະລັດ
SectorBiotechnology
Analyst ratings
Based on 4 analysts giving stock ratings to CRVS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CRVS in the last 3 months.
Highest
Current US$9,41
US$33,00 (+250,69%)
Average
US$29,50 (+213,50%)
Lowest
US$27,00 (+186,93%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
US$30,00
+218,8%
08/11/2026
Sean Lee CFA
H.C. Wainwright
Buy
Maintained
US$27,00
+186,9%
08/10/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
US$33,00
+250,7%
08/07/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
US$33,00
+250,7%
08/07/2026
Etzer Darout
Barclays
Buy
Maintained
US$28,00
+197,6%
08/07/2026
Paul Choi
Goldman Sachs
Buy
Maintained
US$40,00
+325,1%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8,45 ລ້ານ
9,94 ລ້ານ
11,18 ລ້ານ
15,96 ລ້ານ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,12 ລ້ານ
2,28 ລ້ານ
3,70 ລ້ານ
3,33 ລ້ານ
Operating expense
10,57 ລ້ານ
12,22 ລ້ານ
14,88 ລ້ານ
19,30 ລ້ານ
Total operating expenses
10,57 ລ້ານ
12,22 ລ້ານ
14,88 ລ້ານ
19,30 ລ້ານ
Operating income
-10,57 ລ້ານ
-12,22 ລ້ານ
-14,88 ລ້ານ
-19,30 ລ້ານ
Other non operating income
-
-
-
-
EBT including unusual items
-10,16 ລ້ານ
-12,32 ລ້ານ
-13,69 ລ້ານ
-17,96 ລ້ານ
EBT excluding unusual items
-10,16 ລ້ານ
-12,32 ລ້ານ
-13,69 ລ້ານ
-17,96 ລ້ານ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-10,16 ລ້ານ
-12,32 ລ້ານ
-13,69 ລ້ານ
-17,96 ລ້ານ
Net profit margin
-
-
-
-
Earnings per share
-0,12
-0,15
-0,15
-0,19
Interest and investment income
738,00 ພັນ
603,00 ພັນ
1,78 ລ້ານ
2,05 ລ້ານ
Interest expense
-
-
-
-
Net interest expenses
738,00 ພັນ
603,00 ພັນ
1,78 ລ້ານ
2,05 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
-10,54 ລ້ານ
-12,19 ລ້ານ
-14,85 ລ້ານ
-19,26 ລ້ານ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
ແອັບຂອງ Google